BRPI0416679A - formulação farmacêutica estável de eritropoietina - Google Patents

formulação farmacêutica estável de eritropoietina

Info

Publication number
BRPI0416679A
BRPI0416679A BRPI0416679-5A BRPI0416679A BRPI0416679A BR PI0416679 A BRPI0416679 A BR PI0416679A BR PI0416679 A BRPI0416679 A BR PI0416679A BR PI0416679 A BRPI0416679 A BR PI0416679A
Authority
BR
Brazil
Prior art keywords
erythropoietin
pharmaceutical formulation
stable pharmaceutical
formulation
aminomethane
Prior art date
Application number
BRPI0416679-5A
Other languages
English (en)
Inventor
Stefan Arnold
Okke Franssen
Albert Mekking
Original Assignee
Biogenerix Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogenerix Ag filed Critical Biogenerix Ag
Publication of BRPI0416679A publication Critical patent/BRPI0416679A/pt
Publication of BRPI0416679B1 publication Critical patent/BRPI0416679B1/pt
Publication of BRPI0416679B8 publication Critical patent/BRPI0416679B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"FORMULAçãO FARMACêUTICA ESTáVEL DE ERITROPOIETINA". é divulgada uma formulação farmacêutica estável de eritropoietina que contém tris(hidroximetil)aminometano como estabilizante, sendo que a formulação não contém aminoácidos ou albumina de soro humano.
BRPI0416679A 2003-12-01 2004-12-01 formulação farmacêutica estável de eritropoietina BRPI0416679B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03027460.9 2003-12-01
EP03027460A EP1537876A1 (en) 2003-12-01 2003-12-01 Erythropoietin solution formulation
PCT/EP2004/013619 WO2005053745A1 (en) 2003-12-01 2004-12-01 Erythropoietin solution formulation

Publications (3)

Publication Number Publication Date
BRPI0416679A true BRPI0416679A (pt) 2007-02-13
BRPI0416679B1 BRPI0416679B1 (pt) 2018-02-06
BRPI0416679B8 BRPI0416679B8 (pt) 2021-05-25

Family

ID=34442909

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416679A BRPI0416679B8 (pt) 2003-12-01 2004-12-01 formulação farmacêutica estável de eritropoietina

Country Status (17)

Country Link
US (1) US7468351B2 (pt)
EP (2) EP1537876A1 (pt)
AT (1) ATE355081T1 (pt)
AU (1) AU2004294289B2 (pt)
BR (1) BRPI0416679B8 (pt)
CA (1) CA2545880C (pt)
DE (1) DE602004005072T2 (pt)
DK (1) DK1689437T3 (pt)
ES (1) ES2280057T3 (pt)
HR (1) HRP20070062T3 (pt)
NZ (1) NZ546451A (pt)
PL (1) PL1689437T3 (pt)
PT (1) PT1689437E (pt)
RU (1) RU2362581C2 (pt)
SI (1) SI1689437T1 (pt)
WO (1) WO2005053745A1 (pt)
ZA (1) ZA200602340B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120264688A1 (en) 2009-09-23 2012-10-18 Walter Hinderer Process for the purification of recombinant human erythropoietin (epo), epo thus purified and pharmaceutical compositions comprising same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5978124A (ja) * 1982-10-28 1984-05-04 Green Cross Corp:The エリスロポエチンの製法
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
GB8822857D0 (en) * 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
GB9001987D0 (en) * 1990-01-29 1990-03-28 Janssen Pharmaceutica Nv Improved cyclodextrin based erythropietin formulation
DE4014654A1 (de) * 1990-05-08 1991-11-14 Behringwerke Ag Galenische waessrige formulierungen von erythropoietin und ihre verwendung
TW518219B (en) * 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
EP0937456B1 (en) * 1998-02-23 2004-07-21 Cilag AG International Erythropoietin liposomal dispersion
US6979442B1 (en) * 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
ES2216447T3 (es) * 1998-08-17 2004-10-16 Pfizer Products Inc. Composiciones proteicas estabilizadas.
US20040022861A1 (en) * 2001-01-30 2004-02-05 Williams Robert O. Process for production of nanoparticles and microparticles by spray freezing into liquid
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
DE10161577B4 (de) * 2001-12-14 2008-01-10 Scil Proteins Gmbh Verfahren zur Renaturierung von Proteinen

Also Published As

Publication number Publication date
RU2362581C2 (ru) 2009-07-27
AU2004294289B2 (en) 2010-07-22
NZ546451A (en) 2008-08-29
BRPI0416679B8 (pt) 2021-05-25
CA2545880A1 (en) 2005-06-16
WO2005053745A1 (en) 2005-06-16
EP1537876A1 (en) 2005-06-08
DK1689437T3 (da) 2007-05-21
DE602004005072T2 (de) 2007-06-21
CA2545880C (en) 2011-08-30
EP1689437A1 (en) 2006-08-16
PT1689437E (pt) 2007-03-30
ATE355081T1 (de) 2006-03-15
US7468351B2 (en) 2008-12-23
SI1689437T1 (sl) 2007-06-30
BRPI0416679B1 (pt) 2018-02-06
US20070128231A1 (en) 2007-06-07
HRP20070062T3 (en) 2008-05-31
ES2280057T3 (es) 2007-09-01
EP1689437B1 (en) 2007-02-28
DE602004005072D1 (de) 2007-04-12
RU2006123317A (ru) 2008-01-20
PL1689437T3 (pl) 2007-06-29
ZA200602340B (en) 2007-08-29
AU2004294289A1 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
CY1105362T1 (el) Παραγωγα σουλφοναμιδιου, η παρασκευη τους και η εφαρμογη αυτων ως φαρμακα
BR0308452A (pt) composições farmacêuticas e métodos de preparação de composição farmacêutica
BRPI0307702B8 (pt) formulações de solução contendo anticorpo
BRPI0317696B8 (pt) composição para branqueamento
ATE490788T1 (de) Antivirale phosphonate analoge
BR0116032A (pt) imidazoquinolinas substituìdas com sulfonamido éster
ATE464902T1 (de) Stabile pharmazeutische zubereitungen von montelukast-natrium
BR0313733A (pt) Uso da proteìna n beta cinase
MA27175A1 (fr) Formulations hfa de beta2-agonistes a action prolongee de derives de 2(1h)-quinolinone.
BRPI0418133A2 (pt) pró-fármaco de florfenicol tendo solubilidade em água melhorada
DE60329237D1 (de) Kristalline form von linezolid
HN2002000247A (es) Derivados de sulfonamida
CR9223A (es) 18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas,asi como preparaciones farmaceuticas que las contienen
HN2002000332A (es) Sales de acido succinico de 5,7,14 triazatetraciclo (10. 3.1.02.11.04,9)-hexadeca-2 (11), 3,5,7,9-pentaeno y composiciones farmaceuticas de las mismas
CY1105028T1 (el) Υποκατεστημενες c-ιμιδαζο-[1,2-α]πυριδιν-3-υλο-μεθυλαμινες
HN2003000038A (es) Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico
CY1110913T1 (el) Παραγωγα 2-πυρρολιδιν-2-υλο-[1,3,4]-οξαδιαζολης και η χρησιμοποιηση τους σαν αντικαταθλιπτικα
CY1105019T1 (el) Υποκατεστημενες c-ιμιδαζο-[1,2-α]πυριδιν-3-υλο-μεθυλαμινες
CY1105275T1 (el) Ενωσεις υποκατεστημενης γ-λακτονης ως ανταγωνισται - νμda
CY1106446T1 (el) 5-υποκατεστημενα -αλκυλαμινοπυραζολικα παραγωγα ως παρασιτοκτονα
ATE493432T1 (de) Gewinnung von hitzeschockproteinen
BRPI0416679B8 (pt) formulação farmacêutica estável de eritropoietina
BRPI0411208A (pt) uso de derivados 2-amino-1,3-propanodiol para a fabricação de um medicamento para o tratamento de vários tipos de dor
UY29133A1 (es) Amidas conteniendo (!!2-tert-butil-1-(tetrahidro-2h-piran-4-ilmetil)-1h-bencimidazol-5-!!) (metil)amino!sulfonilo) como sustituyente. procedimiento de preparacion, composiciones que lo contienen y aplicaciones
ATE398134T1 (de) Neue analoga von nitrobenzylthioinosin

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 47/00; A61P 7/06

Ipc: A61K 47/00 (2011.01), A61P 7/06 (2011.01)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: BIOGENERIX GMBH (DE)

B25A Requested transfer of rights approved

Owner name: RATIOPHARM GMBH (DE)

B25G Requested change of headquarter approved

Owner name: RATIOPHARM GMBH (DE)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/12/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B15V Prolongation of time limit allowed